Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Sells $23,160.60 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley sold 25,734 shares of the company’s stock in a transaction on Monday, October 11th. The stock was sold at an average price of $0.90, for a total transaction of $23,160.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ ABEO traded down $0.02 during trading on Wednesday, hitting $0.88. 830,720 shares of the company’s stock traded hands, compared to its average volume of 2,154,485. The stock has a fifty day moving average of $1.20 and a two-hundred day moving average of $1.44. Abeona Therapeutics Inc has a 12-month low of $0.84 and a 12-month high of $3.79. The firm has a market cap of $89.11 million, a P/E ratio of -1.55 and a beta of 1.43.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Thursday, July 29th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). On average, sell-side analysts anticipate that Abeona Therapeutics Inc will post -0.65 earnings per share for the current year.

ABEO has been the topic of a number of research analyst reports. Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 22nd. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, October 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $3.65.

A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. Millennium Management LLC purchased a new stake in Abeona Therapeutics during the second quarter valued at about $2,137,000. Morgan Stanley boosted its holdings in shares of Abeona Therapeutics by 242.6% during the second quarter. Morgan Stanley now owns 1,815,198 shares of the biopharmaceutical company’s stock worth $2,833,000 after purchasing an additional 1,285,445 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Abeona Therapeutics by 193.1% during the first quarter. JPMorgan Chase & Co. now owns 1,913,541 shares of the biopharmaceutical company’s stock worth $3,598,000 after purchasing an additional 1,260,682 shares during the period. BlackRock Inc. boosted its holdings in shares of Abeona Therapeutics by 21.8% during the first quarter. BlackRock Inc. now owns 4,980,925 shares of the biopharmaceutical company’s stock worth $9,364,000 after purchasing an additional 890,095 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in shares of Abeona Therapeutics by 254.0% during the first quarter. Nuveen Asset Management LLC now owns 1,118,934 shares of the biopharmaceutical company’s stock worth $2,104,000 after purchasing an additional 802,843 shares during the period. Institutional investors and hedge funds own 27.51% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Story: Understanding dividend yield and dividend payout ratio

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.